ARTMS’ system may ease cost, shortage of valuable radioisotopes

This article was originally published here

ARTMS Products (Vancouver, B.C) has won the CE mark for its first-in-class, advanced technology Quantm irradiation system, designed to produce high-value medical imaging isotopes such as technetium-99m (Tc-99m) on medical cyclotrons.

Tc-99m is given to nearly 50,000 Americans every day to diagnose cancer and heart disease. It is used in more than 80% of all nuclear medicine imaging procedures globally, including those for oncology, urology and neurology. The light-emitting isotope is made by bombarding Molybendum-99 (moly-99) with neutrons. The temporary shutdown of two reactors that produced moly-99 led to a global shortage in 2009-10.

The only North American reactor that produced moly-99, in Chalk River, Ontario, produced 40% of the U.S. supply and closed in March. Others are located in Australia, Europe and South Africa. Because of the short half-life and value of moly-99, shipping is costly.  SHINE Medical Technologies is developing a 57,000-square-foot medical isotope manufacturing plant in Janesville, Wisc.

Get the full story on our sister site, Medical Design & Outsourcing.

The post ARTMS’ system may ease cost, shortage of valuable radioisotopes appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply